Drug intelligence / Profile preview

GSK2830929A

Development stage: Phase 2
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics

Overview

**GSK2830929A** is an investigational pneumococcal vaccine formulation developed by GlaxoSmithKline (GSK). It is designed to protect against Streptococcus pneumoniae infections through immunogenicity against multiple pneumococcal serotypes. The vaccine was evaluated in Phase II clinical trials for safety, reactogenicity, and immune response compared to other formulations, targeting prevention of pneumococcal disease in various populations.

Other names: 2830929A

Beyond the preview

Go deeper on GSK2830929A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2830929A.

Explore the full profile